TuHURA draws two more tranches on Parkview credit line, each for $650,000

TuHURA Biosciences, Inc. disclosed two separate drawdowns under its revolving credit facility with Parkview Holdings One LLC in a pair of 8-K filings dated September 17 and September 24, 2026.

The underlying facility was established earlier in the year. On April 21, 2026, TuHURA entered into a Loan Agreement with Parkview Holdings One LLC as lender, providing for a revolving credit facility that matures on April 21, 2031, with a maximum loan availability of $50 million.¹

Under that facility, TuHURA borrowed $650,000 on September 14, 2026, and again borrowed $650,000 on September 21, 2026, in each case expecting to use the funds for general corporate purposes.¹

The company noted in both filings that the description of the Loan Agreement in the filings is not complete and is qualified by the full text of the agreement, which was filed as Exhibit 4.1 to the company's 8-K filed on April 22, 2026.¹

Each filing also carried standard forward-looking-statement language, flagging risks that TuHURA could fail to meet the conditions needed to draw further funds or stay in compliance with the loan's terms, that the facility's funds might not be enough to cover its operating and development needs, and that potential conflicts of interest could arise from the Loan Agreement given its ties to an affiliate of the company's largest stockholder.¹

Both 8-Ks were signed by Chief Financial Officer Dan Dearborn, with the September 14 draw reported on September 17, 2026, and the September 21 draw reported on September 24, 2026.